ClinicalTrials.gov
public full text
Public Domain
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
Phase II, open-label, single-arm study of CD40/Dectin-1 immunotherapy as maintenance treatment in patients with unresectable pancreatic ductal adenocarcinoma (PDA) who have not progressed following 4-8 months of first line (1L) chemotherapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer#904471
- EUS-RFA PANCARDINAL-1 Trial#896504
- Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients#866656
- Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors#861912
- Preclinical evidence for cytokine-based immunotherapy in pancreatic cancer treatment: A systematic review#425630
Record · ID 1138358
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive